Targeting endothelial oestrogen receptor α non-nuclear signalling might be a new strategy to treat heart failure through nitric oxide (NO)-soluble guanylate cyclase (sGC)-protein kinase G activation without oestrogen’s various unfavourable effects. The gene discussed is SGCB; the disease is heart failure.